Home › NCT07548632
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
RecruitingPhase 2/3
A Phase 2b/3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Physician diagnosis of Dry Eye Disease in the past 6 months * Use of over-the-counter tears * Must agree to genotype testing Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.
About the study
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
What is being tested
- Artificial Tear Run-in (other)
- licaminlimab (drug)
- Vehicle of licaminlimab (other)
Sponsor: Oculis · Participants: 160 · Started: Apr 16, 2026
Contact the study team
- Oculis Chief Development Officer · Phone: 617 928 5886
Official record on ClinicalTrials.gov — NCT07548632
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.